D. Deacon

发表

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

V. Engelhard, C. Slingluff, W. Grosh, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Growth factor-dependent proliferative stimulation of hematopoietic cells is associated with the modulation of cytoplasmic and nuclear 68-Kd calmodulin-binding protein.

P. Quesenberry, D. Deacon, G. Reddy, 1992, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Stromal Regulation of Hematopoiesis

P. Quesenberry, D. Deacon, D. Temeles, 1989, Annals of the New York Academy of Sciences.

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

N. Wages, C. Slingluff, W. Grosh, 2019, Journal of Immunotherapy for Cancer.

Preventing the Spontaneous Modification of an HLA-A2-Restricted Peptide at an N-Terminal Glutamine or an Internal Cysteine Residue Enhances Peptide Antigenicity

J. Shabanowitz, D. Hunt, V. Engelhard, 2004, Journal of immunotherapy.

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients

V. Engelhard, W. Grosh, G. Petroni, 2001, International journal of cancer.

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens

D. Hunt, V. Engelhard, C. Slingluff, 2000, Cancer Immunology, Immunotherapy.

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist

C. Slingluff, W. Grosh, W. Olson, 2021, Journal for ImmunoTherapy of Cancer.

Mutant Cu,Zn superoxide dismutase in motor neuron disease.

C. Slingluff, S. L. Gonias, D. Deacon, 1998 .

The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides

C. Slingluff, G. Petroni, J. Patterson, 2012, Journal of immunotherapy.

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes

C. Slingluff, W. Grosh, W. Olson, 2014, Journal of Immunotherapy for Cancer.

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

F. Marincola, R. Clark, N. Wages, 2016, Cancer Immunology, Immunotherapy.

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome

C. Slingluff, J. Patterson, D. Deacon, 2016, Oncoimmunology.

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases

F. Marincola, N. Wages, C. Slingluff, 2016, Cancer Immunology, Immunotherapy.

Growth factor modulated calmodulin-binding protein stimulates nuclear DNA synthesis in hemopoietic progenitor cells.

P. Quesenberry, D. Deacon, G. Reddy, 1994, Biochemistry.

This information is current as Melanoma Cell Responses in a Long-Term Survivor of Sequential Immune Escape and Shifting of T Ferrone

V. Engelhard, C. Slingluff, S. Ferrone, 2005 .

Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate

L. Zitvogel, G. Kroemer, C. Slingluff, 2016, Oncoimmunology.

Multifactor stimulation of megakaryocytopoiesis: effects of interleukin 6.

P. Quesenberry, S. Clark, D. Deacon, 1991, Experimental hematology.

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

C. Slingluff, J. Patterson, D. Deacon, 2012, Cancer research.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

F. Marincola, G. Coukos, D. Bedognetti, 2016, Oncoimmunology.

MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.

V. Engelhard, M. Conaway, C. Slingluff, 2014, Cancer research.

Effects of rrSCF on multiple cytokine responsive HPP-CFC generated from SCA+Lin- murine hematopoietic progenitors.

P. Quesenberry, D. Deacon, P. Lowry, 1991, Experimental hematology.

Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors

V. Engelhard, C. Slingluff, M. Bosenberg, 2019, Cancer Immunology, Immunotherapy.

The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines

C. Slingluff, J. Patterson, D. Deacon, 2008, BMC Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

C. Slingluff, W. Grosh, W. Olson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

E. Bissonette, C. Slingluff, W. Grosh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis

C. Slingluff, G. Petroni, J. Patterson, 2010, Journal of Translational Medicine.

A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence

C. Slingluff, W. Grosh, S. Gnjatic, 2013, Cancer Immunology, Immunotherapy.

TLR2/6 agonists and interferon‐gamma induce human melanoma cells to produce CXCL10

C. Slingluff, W. Olson, E. Wang, 2015, International journal of cancer.

Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials

C. Slingluff, G. Petroni, A. Hickman, 2021, Cancer Immunology, Immunotherapy.

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

C. Slingluff, W. Grosh, W. Olson, 2015, Cancer Immunology, Immunotherapy.

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

N. Wages, W. Grosh, W. Olson, 2021, Journal for ImmunoTherapy of Cancer.

VEGFR‐2 expression in human melanoma: Revised assessment

C. Slingluff, D. Brautigan, J. Patterson, 2011, International journal of cancer.

Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma 1

V. Engelhard, C. Slingluff, S. Ferrone, 2005, The Journal of Immunology.

Competition Among Peptides in Melanoma Vaccines for Binding to MHC Molecules

V. Engelhard, R. Pierce, C. Slingluff, 2004, Journal of immunotherapy.

Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies

Nolan A Wages, N. Wages, C. Slingluff, 2016, Cancer Immunology, Immunotherapy.

Further studies on growth factor production by the TC-1 stromal cell line: Pre-B stimulating activity

P. Isakson, P. Quesenberry, D. Deacon, 1990 .

Further studies on growth factor production by the TC-1 stromal cell line: pre-B stimulating activity.

P. Isakson, D. Deacon, B. Robinson, 1990, Blood.

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

V. Engelhard, C. Slingluff, W. Grosh, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Stem cell factor induction of in vitro murine hematopoietic colony formation by "subliminal" cytokine combinations: the role of "anchor factors".

P. Quesenberry, D. Deacon, H. McGrath, 1992, Blood.

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

C. Slingluff, W. Grosh, W. Olson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.